The addition of KMR Group and MCC positions WCG’s Market Insights and Intelligence Division as the preeminent clinical trial benchmarking and research service in the industry.
Princeton, NJ – July. 25, 2018 – WIRB-Copernicus Group® (WCG™), the leading provider of solutions to measurably improve the quality and efficiency of clinical research, has acquired KMR Group and Metrics Champion Consortium (MCC), two global leaders in benchmarking, metrics, analytics and performance management in the clinical research and development space.
KMR Group and MCC join clinical trial market research leaders CenterWatch and FDAnews to further strengthen the WCG Market Insights and Intelligence Division. WCG Market Insights and Intelligence provides a suite of trusted benchmarking, databases, market intelligence reports, newsletters, books, conferences and webinars which guide industry decision makers.
“We are delighted to welcome the teams from KMR Group and MCC to WCG and excited to further solidify our role as the industry’s most powerful and reliable source for industry benchmarking,” said Donald A. Deieso, Ph.D., Chairman and CEO of WCG.
“WCG has developed the most robust knowledge base in the industry- a product of our deep relationships with biopharmaceutical companies, CROs, and clinical research sites,” Deieso added. “We embed our extraordinary knowledge base of information within our broad set of clinical services and products, with the goal of improving the conduct of clinical trials. The industry-leading combination of KMR Group and MCC provides our clients unmatched benchmarking data and insights with which to compare their performance with peers. These actionable insights provide clients the advantage of “knowing rather than guessing” in the critical decisions affecting their studies.”
“We are very excited to join WCG and its family of market insights and intelligence services,” said Linda Martin, President of KMR Group. “We believe the alignment of KMR Group into WCG’s Market Insights and Intelligence Division will create and expand the industry’s most trusted and reliable source of evidence with which to plan strategic R&D and to execute clinical studies.”
Linda Sullivan, executive director of MCC added, “We look forward to aligning our leading metrics services and consortiums of clients to WCG’s broader market insights and intelligence solutions. We believe our members and active working groups will see great value in the increased access to rich data sets, benchmarks and publications offered by the companies of WCG and the Market Insights and Intelligence Division.”
Serving the industry for 50 years, WCG is the trusted partner of biopharmaceutical companies, CROs, institutions and central research sites. Comprised of the largest and most highly accredited institutional review boards (IRBs) in the world and a suite of knowledge based clinical services, WCG’s chief focus is on finding ways to accelerate the clinical research process and protect study volunteers.
KMR Group and MCC will operate independently as part of the WCG Market Insights and Intelligence Division. WCG will support the new companies as they continue to expand with access to capital, expertise and corporate operational support.
WCG is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry’s first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection. For more information, please visit www.wcgirb.com, www.wcgclinical.com or follow us on Twitter @WCGClinical or LinkedIn.